Active Not RecruitingNCT05509257
Naltrexone and brain reward responses in teens with eating concerns
About this title
Naltrexone Neuroimaging in Teens With Eating Disorders
Read the official source — NCT05509257Medication studyAges 13–21United StatesEating disorders
Understand this study
Who could participate?
Listed age limits: 13 years to 21 years.
- Listed locations
- Kansas CitySee all locations and recruitment
- Study phase
- Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 17, 2022
- Recruitment status
- Active Not Recruiting
- Enrollment listed in the registry
- 60
- Sponsor
- Children's Mercy Hospital Kansas City
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Early Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
- Locations
- United States
- Age range
- From 13 Years to 21 Years
- Official registry ID
- NCT05509257
- Official title
Show the full official title
Development of a Pharmacodynamic Biomarker of Opioid Antagonism in Adolescents With Eating Disorders
Recruitment & locations
Not recruitingKansas City
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is Children's Mercy Hospital Kansas City, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Naltrexone and Placebo.
Who can participate?
Listed age limits: 13 years to 21 years.
Is this study still recruiting?
The registry lists this study as active, but no longer recruiting.
